InvestorsHub Logo
Followers 119
Posts 4512
Boards Moderated 2
Alias Born 04/14/2014

Re: Millstone post# 65201

Tuesday, 06/14/2016 10:17:15 PM

Tuesday, June 14, 2016 10:17:15 PM

Post# of 460694
LMAO Millsone! big smile big smile big smile I believe this is the forth SCAS that Rosen will suffer dismissal on this year. As stated in the memorandum, even if the company paid for promotion there is nothing illegal or deceitful about that. Judge Furman won't waste 10 minutes deliberating this definitively frivolous litigation.

Re: AAIC details.

From TauRx on their P3 results:

"This Phase 3 programme is now coming to a conclusion but TauRx will not be making any public comments or issuing any statements about the individual trial results until the data from the final study to complete is available for analysis. The company currently plans to make an initial announcement of the results of the first two trials to complete at two presentations at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada on 27th July. Until then, TauRx believes it would be scientifically inappropriate to comment on results as data analysis is still ongoing."
http://taurx.com/clinical-trials/

These studies were completed late last year and are also still awaiting results. TauRx is basing an IPO on them, we might have a $150M secondary riding on ours.

Surely Missling will be speaking at AAIC. The poster title is the same as the original CTAD from last year with 'Dose Dependent' added. Looks placeholder to me.
§


Disclaimer

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News